Modalis gains foundational CRISPR IP access

By The Science Advisory Board staff writers

April 3, 2020 -- Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.

Through the agreement, Modalis will use CRISPR-Guide Nucleotide Directed Modulation (CRISPR-GNDM) technology to create gene therapies for patients with genetic disorders. Financial terms of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.